Ann Thorell
Direttore Finanziario/CFO presso SERES THERAPEUTICS, INC.
Patrimonio netto: 20 495 $ in data 30/04/2024
Profilo
Ann Marella Thorell is currently the Director at Living Beyond Breast Cancer.
She also holds current positions as an Independent Director at ESSA Pharma, Inc., a Director at ApcinteX Ltd., a Director at Carisma Therapeutics, Inc., and the Chief Financial & Accounting Officer at Seres Therapeutics, Inc. In her former roles, Ms. Thorell served as the Chairman at Vallon Pharmaceuticals, Inc. from 2022 to 2023.
She was also the COO, CFO, Secretary & Executive Director at Realm Therapeutics Plc from 2014 to 2019.
Additionally, she held positions as a Director at Capella Bioscience Ltd.
and Z Factor Ltd.
in 2021 and as the CFO, Treasurer, SVP & Chief Accounting Officer at Evelo Biosciences, Inc. in 2023.
Ms. Thorell also has experience as the President of Thorell Consulting and as the Chief Financial Officer at Palladio Biosciences, Inc. from 2019 to 2021.
She served as the Chief Accounting Officer at Centessa Pharmaceuticals Plc from 2021 to 2022.
Ms. Thorell obtained her undergraduate degree from Lehigh University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ESSA PHARMA INC
0.01% | 25/03/2024 | 2 881 ( 0.01% ) | 19 447 $ | 31/05/2024 |
EVELO BIOSCIENCES, INC.
0.12% | 27/11/2023 | 22 778 ( 0.12% ) | 1 048 $ | 30/04/2024 |
Posizioni attive di Ann Thorell
| Società | Posizione | Inizio |
|---|---|---|
| ESSA PHARMA INC. | Direttore/Membro del Consiglio | 31/07/2019 |
| SERES THERAPEUTICS, INC. | Direttore Finanziario/CFO | 25/03/2024 |
| CARISMA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 30/06/2024 |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 29/01/2021 |
| Living Beyond Breast Cancer | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Ann Thorell
| Società | Posizione | Fine |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Direttore Finanziario/CFO | 20/11/2023 |
| GRI BIOPAR | Presidente | 21/04/2023 |
| CENTESSA PHARMACEUTICALS PLC | Comptroller/Controller/Auditor | 31/07/2022 |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Direttore/Membro del Consiglio | 31/07/2022 |
| ░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Ann Thorell
| Lehigh University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| CENTESSA PHARMACEUTICALS PLC | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Realm Therapeutics Plc
 Realm Therapeutics Plc Pharmaceuticals: MajorHealth Technology Realm Therapeutics Plc engages in the development of novel therapeutics. It focuses on the prescription treatments for immune mediated diseases in adults and children. The company was founded on April 21, 2006 and is headquartered in Malvern, PA. | Health Technology |
Thorell Consulting
 Thorell Consulting Miscellaneous Commercial ServicesCommercial Services Thorell Consulting provides business consulting services. The private company is based in New York. | Commercial Services |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
| Living Beyond Breast Cancer | |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |
Capella Bioscience Ltd.
 Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Ann Thorell
